Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 266 participants.
Also called NCT02157298
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 266 participants
- Sponsor
- Registry
-
NCT02157298
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02157298. Randomized; quadruple masking; primary purpose treatment. Start 2014-06 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2016-03-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Dapagliflozin 5 mg
- Intervention (Drug)
- Placebo tablet
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct02157298- Content hash
31421cbcb4c3711eebfa8b3ab5e84a5dcc8630379c19c886e61a2dbd4588512a